Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Return on Equity (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Return on Equity data on record, last reported at 0.59% in Q3 2025.

  • For Q3 2025, Return on Equity fell 18.0% year-over-year to 0.59%; the TTM value through Sep 2025 reached 0.59%, down 18.0%, while the annual FY2024 figure was 0.48%, 8.0% up from the prior year.
  • Return on Equity reached 0.59% in Q3 2025 per VRDN's latest filing, up from 0.61% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.32% in Q4 2022 and bottomed at 1.3% in Q2 2021.
  • Average Return on Equity over 5 years is 0.6%, with a median of 0.49% recorded in 2022.
  • Peak YoY movement for Return on Equity: soared 117bps in 2021, then crashed -33bps in 2023.
  • A 5-year view of Return on Equity shows it stood at 0.41% in 2021, then grew by 20bps to 0.32% in 2022, then tumbled by -103bps to 0.65% in 2023, then surged by 40bps to 0.39% in 2024, then crashed by -52bps to 0.59% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Equity were 0.59% in Q3 2025, 0.61% in Q2 2025, and 0.48% in Q1 2025.